Resolute Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Resolute Advisors’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Hold	89,944	–	–	0.03%	80
2026 Q1	$121K	Hold	89,944	–	–	0.05%	78
2025 Q4	$146K	Hold	89,944	–	–	0.05%	70
2025 Q3	$213K	Hold	89,944	–	–	0.05%	66
2025 Q2	$133K	Hold	89,944	–	–	0.03%	66
2025 Q1	$122K	Hold	89,944	–	–	0.04%	62
2024 Q4	$325K	Buy	89,944 +63,444	+239%	+$153K	0.07%	51
2024 Q3	$57.5K	Hold	26,500	–	–	0.01%	61
2024 Q2	$108K	Buy	26,500 +16,500	+165%	+$113K	0.03%	53
2024 Q1	$106K	Buy	+10,000	New	+$115K	0.02%	52

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Resolute Advisors's MGX Position: Q2 2026 in Review

Resolute Advisors held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 89,944 shares worth $107K. The position accounts for 0.03% of the portfolio, ranked #80.

Resolute Advisors first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $325K in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Resolute Advisors held 89,944 shares of Metagenomi Therapeutics worth $107K as of Q2 2026.
Resolute Advisors left its Metagenomi Therapeutics share count unchanged in Q2 2026.
Metagenomi Therapeutics made up 0.03% of Resolute Advisors's portfolio in Q2 2026, its #80 holding.
Resolute Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
Resolute Advisors's Metagenomi Therapeutics position peaked at $325K in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Resolute Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.